Recent advances in the field of programmable DNA-binding proteins have led to the development of facile methods for genomic localization of genetically encodable entities. Despite the extensive utility of these tools, locus-specific delivery of synthetic molecules remains limited by a lack of adequate technologies. Here we combine the flexibility of chemical synthesis with the specificity of a programmable DNA-binding protein by using protein trans-splicing to ligate synthetic elements to a nuclease-deficient Cas9 (dCas9) in vitro and subsequently deliver the dCas9 cargo to live cells. The versatility of this technology is demonstrated by delivering dCas9 fusions that include either the small-molecule bromodomain and extra-terminal family bromodomain inhibitor JQ1 or a peptide-based PRC1 chromodomain ligand, which are capable of recruiting endogenous copies of their cognate binding partners to targeted genomic binding sites. We expect that this technology will allow for the genomic localization of a wide array of small molecules and modified proteinaceous materials. 
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chemical biology | epigenome engineering | protein delivery | protein semisynthesis | intein splicing A ll eukaryotic genomes are exquisitely packaged into the nucleus as chromatin, wherein DNA is wrapped around histone proteins. To achieve the transcriptional output associated with a particular cell type, chromatin is dynamically decorated with a variety of covalent modifications and effector molecules at specific genetic loci (1, 2) . The resulting epigenomic landscape establishes proper DNA accessibility and genomic structure (3, 4) , and its misregulation can serve as an underlying cause of genetic disorders, including cancer (5) . Thus, deliberate perturbation of chromatin effector function has become a cornerstone for dissecting the molecular mechanisms of transcription regulation pathways in live cells.
The activity of chromatin regulatory proteins can be manipulated using both genetic and pharmacologic approaches (6, 7) . The former includes technologies that alter the total cellular levels of a target transcript through transgene overexpression, knockdown, or knockout, whereas the latter encompasses the use of small-molecule chemical probes that can modulate the functional output of a protein of interest. Although these techniques are capable of globally affecting protein activities, locus-specific epigenomic manipulation has been demonstrated to be a more effective method for probing downstream transcriptional outputs (8) (9) (10) . Targeted epigenome engineering is accomplished by fusing genetically encodable chromatin effector proteins to programmable DNA-binding proteins, such as transcription activator-like effectors (11) , zinc fingers (12) , and nuclease-deficient Cas9 (dCas9) (13) (14) (15) (16) . A complementary approach to the genetic fusion strategy is genomic localization of purely synthetic entities. This opens the door for subnuclear targeting of epigenetic probes, including small molecules and modified proteinaceous material (17, 18) . Examples of synthetic targeting agents include pyrrole-imidazole polyamides and peptide nucleic acids (19, 20) . Despite the elegance of these strategies, however, their widespread application has been limited by the need for specialized chemical synthesis methods and by constraints associated with their genomic targeting (i.e., locus specificity) (19, 21) .
Here, we report a method that combines the versatility of pharmacologic manipulation with the specificity of a genetically programmable DNA-binding protein. Our strategy uses a chemically tailored dCas9 to display a pharmacologic agent at a genetic locus of interest in live mammalian cells (Fig. 1) . This is accomplished using split intein-mediated protein trans-splicing (PTS) to site-specifically link a recombinant dCas9:guide RNA (gRNA) complex to the synthetic cargo of choice (22) . Indeed, we show that the remarkable specificity, efficiency, and speed of PTS allow the direct generation of desired dCas9 conjugates within the cell culture media, thereby facilitating a streamlined "one-pot" approach for genomic targeting of the reaction product. We used this strategy to direct the epigenetic probes JQ1 (a small molecule) and UNC3866 (a modified peptide) to specific genomic loci, where they interact with their target histone recognition domains, the bromodomain and extra-terminal (BET) family bromodomains and Polycomb repressive complex 1 (PRC1) chromodomains, respectively. Therefore, we offer a strategy to direct endogenous epigenetic proteins and macromolecular complexes to specific loci in the absence of genetic manipulation or overexpression of exogenous protein. Furthermore, the highly modular nature of this approach makes it easily adaptable to a wide variety of synthetic entities.
Results
Loci-Specific Delivery of Modified dCas9. Several bioconjugation techniques, including maleimide chemistry and HaloTag labeling, have been used previously to conjugate synthetic moieties, such as biotin and fluorophores, to Cas9 (23, 24) . PTS offers several advantages over these methods that make it ideal for our approach; importantly, reactions can be performed in cell media, are complete within minutes, and do not require downstream purification, thus allowing us to directly deliver the reaction Significance Programmable DNA-binding proteins such as nuclease-deficient Cas9 (dCas9) offer a simple system for genomic localization of genetically encodable biomolecules. These tools have enabled characterization of numerous different chromatin effectors at specific genetic elements. The delivery of fully synthetic cargos to specific loci is currently limited by a lack of adequate technologies. Here we used protein trans-splicing to ligate chemical moieties to dCas9 in vitro and subsequently deliver these molecules to live cells. We demonstrate the effectiveness and versatility of this method by delivering both small-molecule and proteinaceous epigenetic probes to endogenous genomic sites where they interact with their target proteins. This facile and modular strategy will find broad use in locus-specific targeting of chemical cargos to study nuclear processes.
product to cells. In addition, the intein tags are excised from the final construct and thus will not effect Cas9 delivery or downstream applications.
To explore the feasibility of our proposed methodology, we used a PTS reaction to ligate dCas9 to a potent transcriptionactivating peptide, VP64 ( Fig. 2A) . Previous studies have shown that when targeted to the promoter region of genes such as interleukin-1 receptor antagonist (IL1RN) and neurotrophin-3 (NTF3), the dCas9-VP64 fusion protein recruits transcriptional machinery that induces local histone modifications, as well as a buildup of corresponding mRNA levels (10, 25) . This epigenetic and transcriptional plasticity make these regions suitable targets for this study. For our pilot experiment, we generated dCas9-IntN (a genetic fusion of dCas9 and the N-terminal fragment of a split intein) as well as IntC-VP64 (a genetic fusion of the C-terminal fragment of a split intein and VP64) by recombinant protein expression in Escherichia coli (SI Appendix, Fig. S1 ). The requisite gRNAs were generated using an in vitro transcription system (SI Appendix, Fig. S1 and Table S1 ). Once purified, the three delivery components were mixed, and the PTS reaction was monitored by an SDS/PAGE gel shift assay that detects conversion of dCas9-IntN to dCas9-VP64 ( Fig. 2B and SI Appendix, Fig. S2) . Notably, the PTS reaction was carried out directly in cell media to allow delivery of the complex without further purification, i.e., a one-pot process. We found that the splicing reaction was >90% complete within 20 min, at which point we used a previously reported cationic lipid-mediated delivery strategy (25) to introduce the modified dCas9-gRNA complexes at an optimal concentration of 100 nM into 293T cells (SI Appendix, Fig. S3 ). Delivery of the dCas9-VP64:gRNA complexes into cells led to transcriptional activation of the gRNA target gene, as measured by reverse-transcription quantitative PCR (RT-qPCR) analysis (Fig. 2C) . Moreover, the level of mRNA induction was similar to activation levels observed following delivery of the recombinantly expressed dCas9-VP64 genetic fusion protein counterpart (SI Appendix, Fig. S4 ), and the signal was completely Fig. 1 . Strategy for localizing synthetic molecules to specific genomic loci using a modified CRISPR/Cas9 system. Purified dCas9-IntN, IntC-cargo, and gRNAs are mixed in a one-pot reaction (1) to afford a dCas9-cargo:gRNA complex along with the excised intein fragments. This reaction mixture is then directly delivered to live cultured cells using a cationic lipid-mediated transfection strategy (2) . Once inside the cell, the dCas9-cargo:gRNA complex enters the nucleus and binds to its target DNA sequence, resulting in localized activity of the synthetic cargo (3). (1) and IntC-VP64-HA yields the dCas9-NLS-VP64-HA delivery product (2) and the inert split intein complex. (B) The reaction from A as monitored by an SDS/PAGE gel shift assay. The dCas9-NLS-IntN starting material (1) undergoes conversion to the dCas9-NLS-VP64 delivery product (2) (96% in 20 min as measured by densitometry). This reaction was performed using 1 μM of (1), 2 μM IntC-VP64-HA, and a total of 1 μM of IL1RN gRNAs. The gel was imaged using Coomassie brilliant blue stain. (C) Gene activation in the presence of different dCas9-cargo molecules delivered into 293T cells. ΔVP64 represents cargo in which the VP64 sequence has been replaced with a cysteine residue. dCas9-cargo fusions were generated via PTS. Cells were incubated for 20 h in the presence of a given dCas9 complex (final concentration, 100 nM) before harvesting and subsequent mRNA quantification via RT-qPCR. The relative mRNA level represents the fold increase in signal that is observed relative to an off-target delivery. mRNA signals from all samples are normalized to GAPDH mRNA before fold differences are calculated. Error bars represent SEM from three biological replicates. *P ≤ 0.05; **P ≤ 0.01. (D) 293T cells containing a GFP reporter plasmid that have been treated with dCas9-VP64 protein in complex with either reporter-targeted or off-target gRNAs. Cells were visualized by microscopy at 36 h after dCas9-VP64 transfection. (Scale bar: 100 μm.) abolished when VP64 was deleted from the cargo sequence (Fig.  2C ). Taken together, these results validate our ability to deliver PTS-modified dCas9 to specific genomic loci.
Because the signal from the RNA activation assay represents a population average, we sought to implement a secondary assay to assess the efficiency of dCas9 delivery at the single-cell level. We reasoned that activation of a GFP reporter plasmid would allow us to quantify the percentage of cells with sustained localization of functionally active dCas9, which will be a requirement for many applications of this technology. Delivery of the dCas9-VP64 splice product to 293T cells containing a GFP reporter plasmid led to robust activation of GFP when targeting the upstream activation sequence in the reporter (Fig. 2D) . We also used flow cytometry to quantify the efficiency of delivery, and determined that 30% of cells were GFP-positive (SI Appendix, Fig. S5 ). This is in line with previously reported Cas9 nuclease delivery studies, which found genome editing efficiencies ranging from 30% to 50% in 293T cells when a lipid-based protein transfection approach was used (25, 26) . As noted above, these efficiencies are compatible with common cell-based assays, such as imaging and qPCR-based techniques.
Small-Molecule Conjugation to dCas9. We next asked whether this strategy could be extended to allow ligation of a fully synthetic entity to dCas9-gRNA complexes for cellular delivery. The use of small-molecule epigenetic probes is an attractive option for dCas9 conjugation because it allows for genomically localized modulation of target chromatin effector function, thereby expanding the utility of these pharmacologic tools. A prominent example of an epigenetic effector ligand is the bromodomain inhibitor JQ1 (27) . This molecule interacts with the BET family of proteins and competitively blocks their association with acetyllysine residues on chromatin. In this sense, JQ1 can be considered a stable mimic of the acetyl-lysine mark, which, importantly, cannot be removed through cellular deacetylase activity. We wondered whether a dCas9-JQ1 conjugate would be sufficient for the recruitment of BET proteins to target DNA sequences.
Synthetic access to the dCas9-JQ1 conjugate was accomplished using PTS. In this case, we relied on previous structureactivity data to guide the design of an IntC-JQ1 construct in which the probe was predicted to retain activity (28) . Specifically, the free-acid form of JQ1 was attached via a flexible hydrophilic linker to a cargo peptide bearing a reactive cysteine (SI Appendix, Fig. S6 and Schemes S1 and S2). This JQ1 linker was then ligated via expressed protein ligation to a recombinantly generated polypeptide containing the IntC sequence ( Fig. 3A and SI Appendix, Fig. S7 ). Notably, our synthetic route was designed to be highly modular, allowing other synthetic entities to be easily substituted. This is illustrated by the preparation of a control molecule containing the functionally inactive enantiomer of JQ1, (−)-JQ1 (SI Appendix, Figs. S8 and S9). Importantly, the reaction of these IntC-JQ1 constructs with dCas9-IntN was found to be both rapid and efficient (>90% complete in 20 min), indicating that the PTS reaction is not affected by the chemical nature of the IntC cargo (SI Appendix, Fig. S10 ).
We next asked whether dCas9-tethered JQ1 retained the ability to interact with its cognate binding partners. To this end, we generated a GST-tagged Brd4 construct containing the tandem bromodomain motif (Brd4T; amino acids 49-460) for use in in vitro binding assays with dCas9-JQ1. Consistent with our design, the (Fig. 3B and SI Appendix, Fig. S11 ).
dCas9-JQ1 Recruits Brd4 to Genomic Loci in Live Cells. Encouraged by the in vitro binding assays, we sought to develop a sensitive and facile assay for detection of the dCas9-JQ1-Brd4 interaction in live cells. Accordingly, we established a modified two-hybrid luciferase reporter assay that detects dCas9-JQ1 ("bait") recruitment of a transiently transfected VP64-Brd4T-VP64 fusion protein ("prey") (Fig. 3C) . Cellular delivery of dCas9-JQ1-gRNA complexes that target Gal4 binding sites within the upstream activation sequence of the luciferase reporter plasmid (SI Appendix, Table S1 ) led to an eightfold increase in luciferase signal relative to signal from a control delivery using off-target gRNA sequences (Fig. 3D) . In addition, no stimulation of luciferase signal was observed on delivery of control dCas9 conjugates that either lacked JQ1 (ΔJQ1; SI Appendix, Fig. S12 ) or contained the inactive enantiomer of the drug, (−)-JQ1 (Fig. 3D) . We also performed this assay with a modified prey protein containing mutations in each Brd4T bromodomain (Y97A/Y390A), which are known to ablate JQ1 binding (29) . Unexpectedly, we still observed a threefold increase in luciferase signal when this mutated Brd4T was used in our twohybrid assay (Fig. 3D) . Conceivably, this stimulation might be due to residual binding of dCas9-JQ1 to the mutated Brd4T protein; however, omission of the prey construct altogether led to a similar result (Fig. 3D ). This finding suggests that endogenous BET proteins, which are known transcriptional coactivators (30, 31) , are recruited by dCas9-JQ1 and can activate luciferase expression, albeit to a lesser degree than the VP64-Brd4T-VP64 fusion. Gratifyingly, this activation also could be inhibited by the addition of free JQ1 to these deliveries, whereas dCas9-VP64 activation levels remained unaffected, further validating the role of endogenous BET proteins in gene activation by dCas9-JQ1 (SI Appendix, Fig. S13 ).
We wondered whether increasing the number of JQ1 molecules localized to a specific genetic element would be an effective strategy for enhancing BET protein recruitment levels. In the construct described above, the maximum number of cargo molecules targeted to a locus by a single dCas9 conjugate is equal to the number of gRNA binding sites used. We imagined that increasing the number of JQ1 copies on each dCas9 conjugate would be an effective way to circumvent this limitation. Thus, we designed and synthesized a branched cargo peptide that allows four JQ1 moieties to be displayed (SI Appendix, Figs. S14 and S15 and Schemes S3 and S4). This was subsequently ligated to the IntC polypeptide using our modular expressed protein ligation strategy (Fig. 4A and SI Appendix, Fig. S16 ). This branched construct (IntC-JQ1 × 4) was then reacted with dCas9-IntN to yield dCas9-JQ1 × 4, which retained a robust interaction with Brd4T in vitro, as verified by our GST pull-down assay (SI Appendix, Fig.  S17 ). Remarkably, cellular delivery of the dCas9-JQ1 × 4 construct in complex with gRNA resulted in a 27-fold increase in luciferase activity relative to the signal from an off-target delivery (Fig. 4B) . This presumably reflects improved recruitment of the VP64-Brd4T-VP64 prey construct. The multimeric display strategy also led to an enhanced luciferase signal in the absence of exogenous Brd4T, suggesting improved recruitment of endogenous BET proteins (Fig. 4B) . Thus, increasing the number of probe molecules linked to dCas9 through dendritic display is an effective strategy for increasing the functional output of both exogenous and endogenous copies of BET proteins.
Our observation that both dCas9-JQ1 and dCas9-JQ1 × 4 cause gene activation in the absence of the VP64-Brd4T-VP64 fusion led us to further explore the ability of these conjugates to recruit endogenous BET proteins to designated genomic loci. To first ensure that dCas9-JQ1 × 4 could be localized to endogenous genes, we targeted the construct to the promoter region of either IL1RN or NTF3 and performed a biotin-based ChIP-qPCR assay (bioChIP). This assay, which exploits the splicing-dependent biotin tag present on the JQ1 dendrimer scaffold, showed gRNA-dependent localization of the dCas9 conjugate to the targeted promoters (Fig. 4C) . Encouraged by this result, we then explored whether genomic localization of dCas9-JQ1 × 4 was accompanied by recruitment of endogenous Brd4. Indeed, ChIPqPCR assays using a Brd4-specific antibody revealed locus-specific recruitment of this protein as a function of our targeting system (Fig. 4D) . These results illustrate the ability of our strategy to infiltrate a native cellular environment and redirect endogenous machinery to genomic loci of interest.
Delivery of a Modified Peptide Cargo for Targeted Recruitment of the Endogenous PRC1 Complex. We next sought to deliver an epigenetic probe that specifically interacts with an endogenous multisubunit protein complex. In contrast, genetic fusion methods Fig. 3D ). Assays were performed, and relative luciferase signal was calculated as described for monomeric JQ1 luciferase activation experiments. (C) Binding of delivered dCas9-JQ1 × 4 at IL1RN and NTF3 promoter regions as determined by bioChIP-qPCR. (D) Anti-Brd4 ChIP-qPCR enrichment levels at IL1RN and NTF3 promoter regions when dCas9-JQ1 × 4 was delivered to these sites. In C and D, 293T cells were incubated for 8 h with 100 nM of dCas9-JQ1 × 4:gRNA. Relative biotin or Brd4 enrichment represents the fold increase in percent input observed at the target locus relative to an offtarget delivery. Within each sample, percent input signals at each promoter are normalized to the unmodified RHOB housekeeping gene promoter percent input signal before calculating fold differences. Error bars represent SEM from three biological replicates. *P ≤ 0.05; **P ≤ 0.01.
are less applicable to multisubunit protein complexes, because in most cases, only a single subunit can be fused to the targeting vector. As an ideal candidate for these studies, we chose to focus on the PRC1, an archetypal epigenetic silencing factor involved in establishment of cell identity during development (32) . This complex is composed of a minimum of four protein subunits with varying numbers of homologs, including the chromobox protein family (Cbx) that interacts with modified histone H3 (H3K27me3) to recruit the complex to chromatin (33, 34) . Importantly, a recently developed high-affinity peptide ligand for Cbx proteins, UNC3866 (35) , has a structure and properties that seem well suited for locus-specific PRC1 recruitment via our dCas9 conjugation approach (Fig. 5 A and B) .
Following our established synthetic approach, we generated an IntC-UNC3866 molecule that could be directly spliced onto dCas9-IntN quickly and efficiently (>90% complete in 20 min) (SI Appendix, Figs. S18-S20 and Scheme S5). To confirm that the dCas9-UNC3866 conjugate is able interact with the PRC1 complex, we incubated the molecule with 293T cell lysates and performed a subsequent biotin chemiprecipitation assay. We found that dCas9-UNC3866 was able to specifically pull down multiple components of the PRC1 complex, including the target protein (Cbx4), as well as both subunits of the E3 ligase heterodimer (Ring1b and PCGF4/Bmi1), whereas the dCas9-JQ1 × 4 control molecule interacted specifically with Brd4, as expected (Fig. 5C) .
To confirm successful delivery and localization of dCas9-UNC3866, we again performed a bioChIP-qPCR assay and observed robust localization of the modified delivery molecule at targeted promoters, with >20-fold enrichment at IL1RN and ∼10-fold enrichment at NTF3 (Fig. 5D) . Finally, having shown that dCas9-UNC3866 is capable of binding PRC1 and that it localizes to designated genomic loci after cellular delivery, we interrogated the potential for the conjugate to support targeted genomic recruitment of endogenous PRC1 by performing a ChIP-qPCR assay using a Ring1b-specific antibody. Gratifyingly, we observed specific localization of this PRC1 subunit at dCas9-UNC3866 target sites (Fig. 5E ). This result confirms the localization of multiple PRC1 complex components, because UNC3866 can only recruit Ring1b via its interaction with the Cbx subunits (35) .
Discussion
Genomic localization of synthetic entities holds great promise for dissecting epigenetic mechanisms and other facets of chromatin biology (17) . Progress in this area has been hampered by a lack of techniques for generating facile DNA-binding conjugates with a high degree of sequence specificity. By combining flexible strategies in protein chemistry with the remarkably specific and easily programmable CRISPR/Cas9 system, we have developed a method that we anticipate will be broadly useful for locus-specific targeting of chemical cargos, including epigenetic probes, chemical imaging agents, and other tools for studying nuclear processes. We have shown here that PTS can be used to chemoselectively modify dCas9 with proteinaceous material as well as small molecules. Furthermore, the reaction is complete in minutes and can be performed directly in cell media to allow for streamlined delivery to cells without an additional buffer exchange or purification step.
A key feature of our strategy is its modularity. Different probes can be site-specifically attached to the generic dCas9-IntN building block by incorporating unique payloads into the corresponding IntC-cargo component. Importantly, we have developed an efficient semisynthetic route to the IntC-cargo reactant that provides flexibility in both the chemical nature of the cargo and its architecture. This is illustrated by the generation of IntC components with either small-molecule (JQ1) or synthetic peptide-based (UNC3866) cargos. We also show that incorporation of multiple copies of a synthetic entity onto dCas9 can be accomplished using this method via a dendrimeric display strategy. Ultimately, in the case of JQ1, the increased local concentration of the molecule enabled by this multimeric display proved instrumental in driving a robust functional output at designated genomic loci. Conceivably, this scaffold could be adapted to allow the conjugation of multiple different cargoes to the same dCas9 vehicle. It is also important to note that there are limitations regarding the exact composition of the cargo that can be delivered into live cells using this technique. For example, during the course of this study, we attempted to deliver a dendrimeric version of the UNC3866 molecule containing four copies of the probe (SI Appendix, Figs. S21-S23 and Scheme S6), but although we were able to synthesize this molecule and show splicing onto dCas9, we were unable to detect genomic localization using the bioChIP assay (SI Appendix, Fig. S24 ). It is possible that the size, hydrophobicity, and/or some other property of the molecule prevent it from efficiently penetrating the cells, escaping endosomes, and/or engaging the genome. We also note that other site-specific bioconjugation strategies could be adapted to our approach (36), although we stress that the PTS-based system used in this study is fast and highly efficient, and allows the reaction to be performed directly in the cell culture medium. Regardless, the key concept in this study is the ability to direct a synthetic molecule, such as an epigenetic probe, to a specific region of chromatin using the dCas9-targeting vehicle.
The specific application of the technology presented here involves directing a pharmacologic agent to a designated part of the genome, which in the broader sense is an example of subcellular-targeted (D) Binding of delivered dCas9-UNC3866 at IL1RN and NTF3 promoter regions as determined by bioChIP-qPCR. (E) Anti-Ring1b ChIP-qPCR enrichment levels at IL1RN and NTF3 promoter regions when dCas9-UNC3866 was delivered to these sites. For C and D, 293T cells were incubated for 8 h with 100 nM of dCas9-UNC3866:gRNA. Relative biotin or Ring1b enrichment represents the fold increase in percent input observed at the target locus relative to an offtarget delivery. Within each sample, percent input signals at each promoter were normalized to the RHOB promoter percent input before fold differences were calculated. Error bars represent SEM from three biological replicates. *P ≤ 0.05; **P ≤ 0.01. pharmacology (37) . The present work also offers an alternative to using genetic fusions to dCas9 for genomic localization of chromatin effectors. This would be an attractive option for systems in which the introduction of exogenous DNA is difficult or to be avoided, such as certain primary cell lines (38) , as well as when protein overexpression fails to recapitulate biologically relevant molecules/complexes. We also note that the protein delivery strategy used here results in a pulse of cellular activity rather than the sustained activity associated with overexpression of purely genetic Cas9 fusions. This makes the delivery approach better suited to some problems than to others. We have demonstrated that the method allows for temporally controlled recruitment of complex endogenous factors to specific genetic loci. This naturally lends itself to other pulse-chase type experiments in which delivery leads to an immediate change in the local chromatin environment. By the same token, processes that require more prolonged activity to induce a robust output may be better suited to a purely genetic strategy. For example, transcriptional responses following the delivery of dCas9-activator proteins are typically weaker than those associated with expression of similar constructs (25) .
Genetically encoded programmable DNA-binding proteins have emerged as powerful tools for studying genomic processes (16, 39) . The CRISPR/Cas9 system is especially versatile and shows great promise for exploring the causal biochemical relationships underlying epigenetic regulation. In particular, the ability to genetically fuse a chromatin-modifying enzyme, such as a histone acetyltransferase, to dCas9 and target that activity to a designated genomic locus offers the potential to locally decorate chromatin with a histone mark and then study the functional consequences (10) . However, the specificity and substrate scope of these writer enzymes is not always clear, and, moreover, many appear to be regulated by preexisting modifications on the chromatin substrate, so-called "cross-talk" (40) . One advantage of the present method is its potential to bypass the need for the enzyme altogether by allowing direct genomic targeting of a nominal reaction product, for example, a modified histone peptide. In the application described here, we use chemical probes as a stable surrogate for histone acetyl-lysine (JQ1) and histone trimethylation (UNC3866) marks, and show that it is possible to recruit specific chromatin reader proteins to designated genes. This approach should be adaptable to the delivery of other synthetically accessible "actuators" to chromatin, including histone peptides bearing preinstalled posttranslational modifications, as well as small molecules that target other epigenetic factors (3) . As a further extension, it also should be possible to deliver fluorophores and crosslinkers to specific genomic loci for use in live cell imaging and probing of local protein content or chromatin contact points, respectively. Cumulatively, such chemical tailoring of dCas9 has the potential to unlock a new type of cellular biochemistry research involving precise functionalization of eukaryotic chromatin and leading to a greater understanding of associated regulatory mechanisms.
Materials and Methods
The production of recombinant proteins, gRNA molecules, and splicingcompetent cargo molecules, as well as protocols for all assays and delivery procedures used in this study are described in detail in SI Appendix, Materials and Methods.
